To clarify the role of vimentin as a co-receptor in the SARS-CoV-2 infection, providing an additional therapeutic target that could be valuable considering the severity of the clinical course of this infection and the need for combined therapies.
Drugs or strategies that act in the first steps of the infection through the deterioration of the viral protein Spike2 with the cytoskeletal protein vimentin will be identified. Previous work has shown an interaction between vimentin and the Spike protein of SARS-CoV.
Principal Investigator: Dolores Pérez (CIB)
